Establishing a regulatory framework for phage therapy in China (IMAGE)
Caption
Current situation and proposed future regulatory frameworks for phage therapy in China. Phage therapy was initially conducted as IITs in China. In May 2026, State Council Decree No. 818 introduced the anticipated clinical translation of phage therapy as a new biomedical technology. In the future, phage therapy in China may be developed through two pathways: as a pharmaceutical product or as a new biomedical technology. Clearer and more science-based regulatory frameworks need to be established through collaborative efforts among regulatory authorities, academia, and industry.
Credit
hLife
Usage Restrictions
News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.
License
Original content